ライフサイエンスコーパス: ankylosing

1 d lymphocyte-dependent colitis, seronegative ankylosing arthritis and enthesitis, conditions stereoty

2 ythematosus (1346+/-1011 pg per milliliter), ankylosing spondylitis (1368+/-1162 pg per milliliter),

3 improved significantly after MR imaging for ankylosing spondylitis (29% vs 80%, P < .001), undiffere

4 psoriatic arthritis (5 phase 3 trials), and ankylosing spondylitis (4 phase 3 trials).

5 ren of women had an even higher incidence of ankylosing spondylitis (7.2 [1.5-34], p=0.013) than did

6 an [SD] age, 48.8 [12.1] years), and 977 had ankylosing spondylitis (7.3%; 658 men [67.3%]; mean [SD]

7 ot disease and valve disease associated with ankylosing spondylitis (AKS).

8 systemic lupus erythematosus (SLE) (n = 10), ankylosing spondylitis (AS) (n = 10), primary Sjogren's

9 Ankylosing spondylitis (AS) affects 0.25-1.0% of the pop

10 strated similarities and differences between ankylosing spondylitis (AS) and axial psoriatic arthriti

11 s detailing their application in a number of ankylosing spondylitis (AS) and axial spondyloarthritis

12 mography (MDCT) findings of 41 patients with ankylosing spondylitis (AS) and compared them with pulmo

13 rongly associated with predisposition toward ankylosing spondylitis (AS) and other spondyloarthropath

14 e autoimmune inflammatory arthritis disorder ankylosing spondylitis (AS) and with other related spond

15 Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic inflammatory dis

16 ) affects approximately 40% of patients with ankylosing spondylitis (AS) but also affects patients wi

17 iasis (PSOR), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) from 526 subjects overall.

18 nk/ank mouse develops a phenotype similar to ankylosing spondylitis (AS) in humans.

19 tients with MRI-evident sacroiliitis develop ankylosing spondylitis (AS) in the long term and whether

20 Ankylosing spondylitis (AS) is a chronic inflammatory ar

21 Ankylosing spondylitis (AS) is a chronic inflammatory ar

22 Ankylosing spondylitis (AS) is a chronic inflammatory di

23 Ankylosing spondylitis (AS) is a common and highly famil

24 Ankylosing spondylitis (AS) is a common, highly heritabl

25 We investigated the proposal that ankylosing spondylitis (AS) is associated with unusual E

26 Ankylosing spondylitis (AS) is the prototypic form of Sp

27 erstanding of the gene-regulatory network in ankylosing spondylitis (AS) is vital for elucidating the

28 Ankylosing spondylitis (AS) may present with extra-artic

29 The clinical response in ankylosing spondylitis (AS) patients treated with biolog

30 ment of spinal inflammation in patients with ankylosing spondylitis (AS) relies primarily on magnetic

31 udies of the HLA-B27-transgenic rat model of ankylosing spondylitis (AS) suggested that macrophages d

32 A strong association between ERAP1 and ankylosing spondylitis (AS) was recently identified by t

33 seases of the spine and pelvis (for example, ankylosing spondylitis (AS)) and the eye (that is, acute

34 7 subtypes associated with susceptibility to ankylosing spondylitis (AS), and those reported not to b

35 HC) tag SNPs from 1,000 independent cases of ankylosing spondylitis (AS), autoimmune thyroid disease

36 s I molecule B27 is strongly associated with ankylosing spondylitis (AS), but the pathogenic role of

37 rated high heritability of susceptibility to ankylosing spondylitis (AS), it is only recently that th

38 ld standard of rheumatologists' diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA),

39 l and peripheral articular manifestations of ankylosing spondylitis (AS), psoriatic arthritis (PsA),

40 negative spondyloarthropathies (SpA) include ankylosing spondylitis (AS), psoriatic arthritis (PsA),

41 endoplasmic reticulum aminopeptidase 1) with ankylosing spondylitis (AS), which is restricted to HLA-

42 hat is necessary to establish a diagnosis of ankylosing spondylitis (AS).

43 graphic damage in patients with longstanding ankylosing spondylitis (AS).

44 ntial association with the rheumatic disease ankylosing spondylitis (AS).

45 lity of life (HRQOL) in patients with active ankylosing spondylitis (AS).

46 pathogenic role in the spondylarthropathy of ankylosing spondylitis (AS).

47 sulfapyridine (SP), in patients with active ankylosing spondylitis (AS).

48 formation manifests the clinical feature of ankylosing spondylitis (AS).

49 l disease with rheumatoid arthritis (RA) and ankylosing spondylitis (AS).

50 e treatment of osteoporosis in patients with ankylosing spondylitis (AS).

51 ss I molecules due to their association with Ankylosing Spondylitis (AS).

52 TNFis) have revolutionized the management of ankylosing spondylitis (AS); however, the lack of notabl

53 ciated with the chronic inflammatory disease Ankylosing Spondylitis (AS); however, the mechanisms und

54 ASsessment of Ankylosing Spondylitis (ASAS) International Working Grou

55 D16S516), multiple sclerosis (D12S1052), and ankylosing spondylitis (D16S516).

56 s (EAIR, 0.02; 95% CI, 0.00-0.11), and 2 had ankylosing spondylitis (EAIR, 0.08; 95% CI, 0.01-0.28).

57 = 8), juvenile rheumatoid arthritis (n = 3), ankylosing spondylitis (n = 1), and psoriatic spondylart

58 = 1.33; 95% CI, 1.03-1.72) and negative for ankylosing spondylitis (OR = 0.72; 95% CI, 0.54-0.98) an

59 d IL12B regions convincingly associated with ankylosing spondylitis (P < 5 x 10(-8) in the combined d

60 tients with presumed sarcoidosis compared to ankylosing spondylitis (p = 0.0001), behcet's disease (p

61 ts with presumed sarcoidosis with respect to ankylosing spondylitis (p = 0.0001), behcet's disease, (

62 IBD), and psoriasis, psoriatic arthritis, or ankylosing spondylitis (psoriasis and spondyloarthropath

63 ges of patients achieving the Assessments in Ankylosing Spondylitis 20% response (ASAS20) at weeks 12

64 cases with presence or absence of EIMs (eg, ankylosing spondylitis [ankylosing spondylitis and sacro

65 Reactive arthritis, sacroiliitis, and ankylosing spondylitis also appear to be increased in th

66 residues 528 and 575/725 is associated with ankylosing spondylitis among HLA-B27-positive individual

67 riteria for PsA, a new composite measure for ankylosing spondylitis and axial SpA, the ASDAS, new mea

68 ndyloarthropathic changes closely resembling ankylosing spondylitis and DISH.

69 dies of various physical therapy programs in ankylosing spondylitis and identify their benefits and p

70 has supported novel roles for these drugs in ankylosing spondylitis and in cancer prevention, accumul

71 bserved in phase III trials of patients with ankylosing spondylitis and in trials conducted a decade

72 However, ankylosing spondylitis and inflammatory bowel disease we

73 ecent studies indicate that the morbidity of ankylosing spondylitis and PsA are considerably higher t

74 Three risk loci shared with ankylosing spondylitis and psoriasis (the MHC class I re

75 uding rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis, confirms the impor

76 clude rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis.

77 immune-mediated disorders, most notably with ankylosing spondylitis and psoriasis.

78 of the tumor necrosis factor antagonists in ankylosing spondylitis and psoriatic arthritis has gener

79 necrosis factor inhibitors for patients with ankylosing spondylitis and psoriatic arthritis has had a

80 Sulfasalazine is moderately effective for ankylosing spondylitis and psoriatic arthritis, although

81 The greatest experience has accrued in ankylosing spondylitis and psoriatic arthritis.

82 ved functional status and quality of life in ankylosing spondylitis and psoriatic arthritis.

83 als with tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.

84 are effective and safe for the treatment of ankylosing spondylitis and psoriatic arthritis.

85 cells from healthy donors and patients with ankylosing spondylitis and psoriatic arthritis.

86 Ankylosing spondylitis and related spondylarthritides ar

87 ole for HLA-B27 in genetic susceptibility to ankylosing spondylitis and related spondyloarthropathies

88 cal comparison with originator infliximab in ankylosing spondylitis and rheumatoid arthritis; however

89 ons within major histocompatibility complex (ankylosing spondylitis and sacroiliitis, P = 1.4E-15; OR

90 absence of EIMs (eg, ankylosing spondylitis [ankylosing spondylitis and sacroiliitis], primary sclero

91 Patients with juvenile-onset ankylosing spondylitis appear to have poorer functional

92 or rheumatoid arthritis, where patients with ankylosing spondylitis are offered therapy early in the

93 cant reductions in the signs and symptoms of ankylosing spondylitis at week 16.

94 e for relieving the pain of axial disease in ankylosing spondylitis but these findings contradict two

95 me-wide association study in 2,053 unrelated ankylosing spondylitis cases among people of European de

96 replication in an independent cohort of 898 ankylosing spondylitis cases and 1,518 controls.

97 changes in the course of the disease, Stoke Ankylosing spondylitis classification Spinal Score (SASS

98 oth M-CSF and MMP-3 correlated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) v

99 A modified Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) w

100 cal disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),

101 onset, disease activity assessed by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),

102 ondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),

103 Disease activity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).

104 ter disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (P = 0.002

105 ase activity and functional parameters (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI],

106 nthesitis (using the PsA-modified Maastricht Ankylosing Spondylitis Enthesitis Score [MASES] index).

107 ose with psoriatic arthritis, and those with ankylosing spondylitis from phase III trials of golimuma

108 al assessments included the BASDAI, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Ank

109 ght, VAS scores for entheseal pain, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bat

110 d functional impairment assessed by the Bath Ankylosing Spondylitis Functional Index (BASFI).

111 nal limitations were assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI; score ra

112 ylitis Disease Activity Index [BASDAI], Bath Ankylosing Spondylitis Functional Index [BASFI], and Bat

113 ondylitis Functional Index [BASFI], and Bath Ankylosing Spondylitis Global Index [BASGI]).

114 etween inflammation and structural damage in ankylosing spondylitis has been an important focus of re

115 Medical therapy of ankylosing spondylitis has improved dramatically with th

116 ive arthritis, but an infectious trigger for ankylosing spondylitis has not yet been established.

117 d for patients with rheumatoid arthritis and ankylosing spondylitis have been reported, and generic q

118 at has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial.

119 x in determining increased susceptibility to ankylosing spondylitis in children.

120 that TNFi slows radiographic progression in ankylosing spondylitis in data from clinical trials may

121 osome regions in human genome, which control ankylosing spondylitis in human patients.

122 irst published clinical account of a case of ankylosing spondylitis in the United States.

123 f Life (ASQoL) instrument, the ASsessment in Ankylosing Spondylitis International Working Group crite

124 Ankylosing spondylitis is a common form of inflammatory

125 Ankylosing spondylitis is a genetically determined and c

126 Ankylosing spondylitis is an inflammatory autoimmune dis

127 Ankylosing spondylitis is associated with increased risk

128 IL-1A association further substantiate that ankylosing spondylitis is determined to a large extent b

129 modified New York criteria, the diagnosis of ankylosing spondylitis is made based on the presence of

130 Nearly half of the susceptibility to ankylosing spondylitis is provided by major histocompati

131 One of the major goals of treatment of ankylosing spondylitis is to prevent or slow the develop

132 autoimmune disease and evidence showed that ankylosing spondylitis may be a microbiome-driven diseas

133 ment in spinal mobility metrics and the Bath Ankylosing Spondylitis Metrology Index (BASMI).

134 dation of two new genes, IL23R and ARTS1, in ankylosing spondylitis pathogenesis.

135 shown to be differentially abundant between ankylosing spondylitis patients and healthy controls.

136 A recent trial in ankylosing spondylitis patients demonstrated continuous

137 Specifically, the ankylosing spondylitis patients demonstrated increases i

138 In ankylosing spondylitis patients, IL-6 and LRG-1 were ide

139 emic sclerosis patients and in 3 of 12 (25%) ankylosing spondylitis patients.

140 monly used in probiotics, accumulated in the ankylosing spondylitis patients.

141 ng Spondylitis Functional Index (BASFI), the Ankylosing Spondylitis Quality of Life (ASQoL) instrumen

142 the Short Form 36 (SF-36) Health Survey and Ankylosing Spondylitis Quality of Life (ASQoL) Questionn

143 tis Disease Activity Index (BASDAI), and the Ankylosing Spondylitis Quality of Life (ASQoL) questionn

144 lvis, and hips were scored by using the Bath Ankylosing Spondylitis Radiology Index (BASRI) by an exp

145 pinal radiographs were scored using the Bath Ankylosing Spondylitis Radiology Index for the spine (BA

146 Previously, the diagnosis of ankylosing spondylitis required advanced changes on plai

147 dy reports four genetic loci associated with ankylosing spondylitis risk and identifies a major role

148 before HLA class I presentation, only affect ankylosing spondylitis risk in HLA-B27-positive individu

149 ) a random sample of members of the National Ankylosing Spondylitis Society.

150 bar spine, which were scored using the Stoke Ankylosing Spondylitis Spine Score.

151 of the interleukin-1 (IL-1) region genes in ankylosing spondylitis suggested the susceptibility to b

152 A recent meta-analysis of published scans of ankylosing spondylitis susceptibility has confirmed site

153 on-major histocompatibility complex genes in ankylosing spondylitis susceptibility, and suggests area

154 ocompatibility complex), 10q, 16q and 19q in ankylosing spondylitis susceptibility.

155 nt GWAS on multiple sclerosis, psoriasis and ankylosing spondylitis that inclusion of known covariate

156 ide strong evidence that HLA-B27 operates in ankylosing spondylitis through a mechanism involving abe

157 Exercise therapy should remain a mainstay of ankylosing spondylitis treatment complementing medical t

158 durations may result in a paradigm shift for ankylosing spondylitis treatment similar to that undergo

159 gone substantial change from when the entity ankylosing spondylitis was defined by the modified New Y

160 Ankylosing spondylitis was more prevalent among children

161 50% and 75% of patients were diagnosed with ankylosing spondylitis were ascertained from a database

162 Forty patients with active, inflammatory ankylosing spondylitis were randomly assigned to receive

163 cantly reduces spinal inflammation in active ankylosing spondylitis when compared to placebo; there w

164 s and well tolerated in patients with active ankylosing spondylitis who had an inadequate response or

165 A 58-year-old woman with debilitating ankylosing spondylitis who was born to consanguineous pa

166 esitis-related arthritis progress to develop ankylosing spondylitis within 10 years after presentatio

167 The spondylarthritides (such as ankylosing spondylitis) are multisystem inflammatory dis

168 rthritis, psoriasis/psoriatic arthritis, and ankylosing spondylitis) linked to newborns with periconc

169 e SpA (2 with psoriatic arthritis and 1 with ankylosing spondylitis) were isolated by positive select

170 ing psoriatic arthritis, reactive arthritis, ankylosing spondylitis), and osteoarthritis have charact

171 une hemolytic anemia, pernicious anemia, and ankylosing spondylitis), infectious (pneumonia, hepatiti

172 aphic axial spondyloarthritis (also known as ankylosing spondylitis).

173 relationship between the gut microbiome and ankylosing spondylitis, a quantitative metagenomics stud

174 Evaluating Long-Term Efficacy and Safety in Ankylosing Spondylitis, a randomized controlled study, w

175 mune-mediated diseases, including psoriasis, ankylosing spondylitis, and Behcet disease.

176 patients with systemic lupus erythematosus, ankylosing spondylitis, and hepatic fibrosis.

177 ch as rheumatoid arthritis, IgA nephropathy, ankylosing spondylitis, and inflammatory bowel disease (

178 anding inflammation in rheumatoid arthritis, ankylosing spondylitis, and juvenile chronic arthritis.

179 tion may have structure-modifying effects in ankylosing spondylitis, and may thereby alter the diseas

180 immune diseases such as behcet's disease and ankylosing spondylitis, and ocular involvement of infect

181 se, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, and osteoarthritis.

182 However, anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangit

183 nvestigated one in detail, a risk allele for ankylosing spondylitis, and provide direct evidence of a

184 indications (psoriatic arthritis, psoriasis, ankylosing spondylitis, and rheumatoid arthritis), we te

185 erextensibility, early onset osteoarthritis, ankylosing spondylitis, and seronegative erosive rheumat

186 py not only in RA but also in Crohn disease, ankylosing spondylitis, and several other chronic inflam

187 lgia rheumatica (PMR), giant cell arteritis, ankylosing spondylitis, and Sjogren's syndrome, and to p

188 e of the spondyloarthritides, including PsA, ankylosing spondylitis, and the broader categories of Sp

189 the disease-modifying role of these drugs in ankylosing spondylitis, and their use in the understudie

190 s, two patients with gout, two patients with ankylosing spondylitis, and two patients with psoriatic

191 This group includes 6 entities: ankylosing spondylitis, arthritis associated with inflam

192 h American sample of two new loci related to ankylosing spondylitis, ARTS1 and IL23R, and confirmatio

193 a prospective study involving patients with ankylosing spondylitis, behcet's disease, presumed sarco

194 eased susceptibility and disease activity of ankylosing spondylitis, but the effect of HLA-B27 on the

195 eously investigated the genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, prim

196 0 patients and 45 controls: alopecia areata, ankylosing spondylitis, dermatomyositis, Graves' disease

197 ce of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, familial Mediterranean fever, an

198 Eligible patients had active ankylosing spondylitis, fulfilled modified New York crit

199 esitis in psoriatic arthritis and uveitis in ankylosing spondylitis, have also been observed.

200 principle has relevance to diseases such as ankylosing spondylitis, in which HLA-B27 and ERAP jointl

201 The prototypical type of axSpA, ankylosing spondylitis, is thought to be caused by inter

202 with many immune-mediated diseases including ankylosing spondylitis, multiple sclerosis, and inflamma

203 pproval of Janus kinase (JAK) inhibitors for ankylosing spondylitis, new data on the effect of biolog

204 , rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-infectious uveitis, and mult

205 ebo-controlled RCTs of rheumatoid arthritis, ankylosing spondylitis, optic neuritis, systemic lupus e

206 d arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, or inflammatory bowel disease us

207 indications (psoriasis, psoriatic arthritis, ankylosing spondylitis, or juvenile arthritis), as an ac

208 adults diagnosed with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis and 219 h

209 wel disease, psoriasis, psoriatic arthritis, ankylosing spondylitis, or rheumatoid arthritis exhibite

210 e advances in the pharmacological therapy of ankylosing spondylitis, physical therapy remains an esse

211 RS had a higher significant association with ankylosing spondylitis, polymyositis, psoriasis, rheumat

212 carrying of the spinal cord in the course of ankylosing spondylitis, present in MRI include: bone mar

213 dently linked to inflammatory bowel disease, ankylosing spondylitis, primary sclerosing cholangitis a

214 n the pathogenesis or development process of ankylosing spondylitis, providing new leads for the deve

215 Group criteria for SpA, without evidence of ankylosing spondylitis, psoriasis, inflammatory bowel di

216 recently associated with the pathogenesis of ankylosing spondylitis, psoriatic arthritis and acute an

217 ct in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenil

218 ts and for diseases other than RA, including ankylosing spondylitis, psoriatic arthritis, and polymyo

219 mmatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psorias

220 mmatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psorias

221 uded in the category of spondyloarthropathy (ankylosing spondylitis, psoriatic arthritis, reactive ar

222 ry rheumatic diseases that primarily include ankylosing spondylitis, reactive arthritis, and the arth

223 rheumatological conditions (i.e. psoriasis, ankylosing spondylitis, rheumatoid arthritis, fibromyalg

224 keletal disorders, including osteoarthritis, ankylosing spondylitis, rheumatoid arthritis, heterotopi

225 ccess in psoriasis, psoriatic arthritis, and ankylosing spondylitis, sparking efforts to develop oral

226 biologic DMARDs on structural progression in ankylosing spondylitis, strategy trials on tapering or s

227 r psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, an

228 , psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, Sj

229 c lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, systemic sclerosis, Sjogren synd

230 able and effective structure modification in ankylosing spondylitis, the data strongly suggest a bene

231 As in human ankylosing spondylitis, the MHC was the major permissive

232 To identify susceptibility loci for ankylosing spondylitis, we undertook a genome-wide assoc

233 There are few effective treatments for ankylosing spondylitis, which causes substantial morbidi

234 atibility complex genes in predisposition to ankylosing spondylitis, which will be summarized here.

235 and women differ in their susceptibility to ankylosing spondylitis, with about 2.5 men affected for

236 de over 90% of the overall susceptibility to ankylosing spondylitis, with about half of the genetic c

237 with unlike conformations in differentially ankylosing spondylitis-associated subtypes) must not be

238 initiate autoimmune damage in patients with ankylosing spondylitis-associated subtypes.

239 th inflammatory bowel disease, psoriasis and ankylosing spondylitis.

240 ic target for autoimmune diseases, including ankylosing spondylitis.

241 f exercise and nonpharmacologic therapies in ankylosing spondylitis.

242 on may be of benefit to select patients with ankylosing spondylitis.

243 psoriatic arthritis, reactive arthritis, or ankylosing spondylitis.

244 espect to understanding the genetic basis of ankylosing spondylitis.

245 pus erythematosus, rheumatoid arthritis, and ankylosing spondylitis.

246 ists are effective for signs and symptoms of ankylosing spondylitis.

247 s and spinal deformities similar to those in ankylosing spondylitis.

248 en shown to be effective in the treatment of ankylosing spondylitis.

249 dissection of the genetic susceptibility to ankylosing spondylitis.

250 otential role in delaying the progression of ankylosing spondylitis.

251 itis and to attenuate spinal inflammation in ankylosing spondylitis.

252 antagonists can prevent structural damage in ankylosing spondylitis.

253 b were also effective in phase III trials in ankylosing spondylitis.

254 thritis can be asymptomatic, as in classical ankylosing spondylitis.

255 , inflammatory bowel diseases, psoriasis, or ankylosing spondylitis.

256 or (p75):Fc fusion protein, in patients with ankylosing spondylitis.

257 , and sustained improvement in patients with ankylosing spondylitis.

258 in Sardinia, seem not to be associated with ankylosing spondylitis.

259 children or siblings of female patients with ankylosing spondylitis.

260 pathway is a potential therapeutic target in ankylosing spondylitis.

261 report human TRBV9(+) T cell elimination in ankylosing spondylitis.

262 a selective JAK1 inhibitor, in patients with ankylosing spondylitis.

263 ons like psoriasis, psoriatic arthritis, and ankylosing spondylitis.

264 been shown to be effective in patients with ankylosing spondylitis.

265 icrobiome are associated with development of ankylosing spondylitis.

266 sistent with the overall lack of efficacy in ankylosing spondylitis.

267 ondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.

268 rials of secukinumab in patients with active ankylosing spondylitis.

269 ording to the modified New York criteria for ankylosing spondylitis.

270 s Crohn's disease, rheumatoid arthritis, and ankylosing spondylitis.

271 e epistatic association of both molecules in ankylosing spondylitis.

272 orm of axial spondyloarthropathies, which is ankylosing spondylitis.

273 -7.0) for psoriasis, psoriatic arthritis, or ankylosing spondylitis.

274 -B27 subtypes differentially associated with ankylosing spondylitis.

275 inflammatory diseases, notably psoriasis and ankylosing spondylitis.

276 rmatomyositis; 16 had scleroderma; eight had ankylosing spondylitis; five had juvenile RA; three had